Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer

Balkan Medical Journal

Volumn 32, Issue 1, 2015, Pages 89-95

  Erbaş, Hakan ^a   Bal, Oğuz ^a   Çakır, Erol ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Arginase; Breast cancer; Ornithine; Polyamines; Rosuvastatin

Indexed keywords

ARGINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ORNITHINE; POLYAMINE; PUTRESCINE; ROSUVASTATIN; SPERMIDINE; SPERMINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER TISSUE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXPERIMENTAL MAMMARY NEOPLASM; MALE; MOUSE; NONHUMAN; TISSUE LEVEL;

EID: 84922948591     PISSN: 21463123     EISSN: 21463131     Source Type: Journal    
DOI: 10.5152/balkanmedj.2015.15611     Document Type: Article

References (35)

1. Jenkinson CP, Grody WW, Caderbaum SD. Comparative properities of arginases. Comp Biochem Physiol B Biochem Mol Biol 1996;114:107-32. [CrossRef]
2. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. Arginases I and II: do their functions overlap? Mol Genet Metab 2004;81:S38-44. [CrossRef]
3. Porembska Z, Luboinski G, Chrzanowska A, Mielczarek M, Magnuska J, Baranczyk-Kuzma A. Arginase in patients with breast cancer. Clin Chim Acta 2003;328:105-11. [CrossRef]
4. Lowe DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 2000;4:441-58. [CrossRef]
5. Bonavida B, Khineche S, Huerta-Yepez S, Garban H. Therapeutic potential of nitric oxide in cancer. Drug Resist Updat 2006;9:157-73. [CrossRef]
6. Singh R, Avliyakulov NK, Braga M, Haykinson MJ, Martinez L, Singh V, et al. Proteomic identification of mitochondrial targets of arginase in human breast cancer. PLoS One 2013;8:115. [CrossRef]
7. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001;58:244-58. [CrossRef]
8. Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. Biochem J 2003;376:1-14. [CrossRef]
9. Park MH, Igarashi K. Polyamines and their metabolites as diagnostic markers of human diseases. Biomol Ther (Seoul) 2013;21:1-9. [CrossRef]
10. Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol 2012;6:17-33.
11. Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. J Cardiovasc Pharmacol 2007;49:376-83. [CrossRef]
12. Schupp N, Schmid U, Heidland A, Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis 2008;199:278-87. [CrossRef]
13. Kotamraju S, Williams CL, Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 2007;67:7386-94. [CrossRef]
14. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. Th1/Th2- regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 1999;163:3771-7.
15. Erbas H, Aydogdu N, Usta U, Erten O. Protective role of carnitine in breast cancer via decreasing arginase activity and increasing nitric oxide. Cell Biol Int 2007;31:1414-9. [CrossRef]
16. Fu S, Xiao C, Zhao W, Yu X. Polyamines analysis by HPLC and their application as tumor markers. Frontiers Biosci (Elite Ed.) 2012;4:1795-801.
17. Ishii N, Ikenaga H, Carmines PK, Aoki Y, Ogawa Z, Saruta T, et al. High glucose augments arginase activity and nitric oxide production in the renal cortex. Metabolism 2004;53:868-74. [CrossRef]
18. Jansen A, Lewin S, Cattell V, Cook HT. Arginase is a major pathway of L-arginine metabolism in nephritic glomeruli. Kidney Int 1992;42:1107-12. [CrossRef]
19. Durak I, Oztürk HS, Elgün S, Cimen MY, Yalçin S. Erythrocyte nitric oxide metabolism in patients with chronic renal failure. Clin Nephrol 2001;55:460-4.
20. Grody WW, Dizikes GJ, Cederbaum SD. Human arginase isozymes. Isozymes Curr Top Biol Med Res 1987;13:181-214.
21. Griffith OW, Stuehr DJ. Nitric oxide synthases. Properties and catalytic mechanism. Ann Rev Physiol 1995;57:707-36. [CrossRef]
22. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines. N(omega)- hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 2000;60:3305-12.
23. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995;92:4392-6. [CrossRef]
24. Edwards P, Cendan JC, Topping DB, Moldawer LL, MacKay S, Copeland EM, et al. Tumour cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung metastasis in vivo. J Surg Res 1996;63:49-52. [CrossRef]
25. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 1994;91:9407-11. [CrossRef]
26. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003;34:955-68. http://dx.doi.org/10.1016/S0891-5849(02)01363-1. [CrossRef]
27. Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumour cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 1994;54:2462-7.
28. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-34. [CrossRef]
29. Gotoh T, Araki M, Mori M. Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA. Biochem Biophys Res Commun 1997;233:487-91. [CrossRef]
30. Bachrach U. Polyamines and cancer: minireview article. Amino Acids 2004;26:307-9. [CrossRef]
31. Gugliucci A. Polyamines as clinical laboratory tools. Clin Chim Acta 2004;344:23-35. [CrossRef]
32. Sumi S, Beauchamp RD, Townsend CM, Uchida T, Murakami M, Rajaraman S, et al. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 1992;103:982-9.
33. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92. [CrossRef]
34. Lai SW, Liao KF, Lai HC, Muo CH, Sung FC, Chen PC. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol 2013;28:485-92. [CrossRef]
35. Seiler N. Catabolism of polyamines. Amino Acids 2004;26:217-33. [CrossRef]